

# 1 SPIN-dvEvo: Exploration of vast functional sequence 2 space by directed virtual evolution from a local sequence 3 cluster

4 Zhihang Chen<sup>1,2§</sup>, Jinle Tang<sup>3§</sup>, Tingkai Zhang<sup>3,4§</sup>, Xing Zhang<sup>3</sup>, Qinghui Nie<sup>2,3</sup>, Jian Zhan<sup>3,5,6\*</sup>, and  
5 Yaoqi Zhou<sup>1,3\*</sup>

6

7 <sup>1</sup>Tsinghua University, Beijing 100084, China

8 <sup>2</sup>Shenzhen Medical Academy of Research and Translation (SMART), Shenzhen, 518107, China

9 <sup>3</sup>Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518107, China

10 <sup>4</sup>School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China

11 <sup>5</sup>Ribopeutic (Shenzhen) Co., Ltd., Futian, Shenzhen, 518000, China

12 <sup>6</sup>Ribopeutic Inc., Qiantang, Hangzhou, 310018, China

13

14 <sup>§</sup>Co-first authors. These authors are contributed to the manuscript equally.

15 \*Corresponding authors: Yaoqi Zhou, +86-(755) 2684 6275, [zhouyq@szbl.ac.cn](mailto:zhouyq@szbl.ac.cn); Jian Zhan, +86-(755) 2684 6275, [zhanjian@szbl.ac.cn](mailto:zhanjian@szbl.ac.cn)

17

## 18 Abstract

19 Both natural and directed evolution are powerful in improving protein functions but they are slow  
20 in exploring the nearly endless sequence space. Here, we present SPIN-dvEvo that couples few-shot  
21 low-rank adaptation (LoRA) of an ESM-2 protein language model with a genetic algorithm to  
22 quickly evolve functional remote homologs from a local cluster of highly-homologous, binary-  
23 labeled sequences. We experimentally tested SPIN-dvEvo on an enzyme (the core deaminase  
24 component of adenine base editors, TadA) and an intrinsically disordered protein (antitoxin CcdA).  
25 In TadA, virtually evolved sequences with low sequence identity to the starting sequences achieved  
26 a 38% success rate (23/60) in the first round and a 51% success rate along with a one-order-of-  
27 magnitude improvement in enzymatic activity in the second round, for which SPIN-dvEvo was  
28 retrained on first-round labels. Virtual evolution of the disordered protein CcdA was also successful,  
29 albeit at low success rate of 2.6%. Thus, SPIN-dvEvo can simulate billions of years of evolution  
30 in just minutes, rapidly creating new functional clusters.

## 31 Introduction

32 Directed evolution is a central strategy for engineering functional proteins, enabling stepwise  
33 improvement of enzymes and binders directly in the laboratory through iterative cycles of  
34 mutagenesis, selection, and amplification. It has produced catalysts with enhanced activity, altered  
35 specificity, and improved stability for applications ranging from therapeutics to industrial  
36 biocatalysis<sup>1, 2</sup>. Despite these successes, both natural and laboratory evolution remain intrinsically

37 constrained by the locality of accessible mutational steps: most variants that can be efficiently  
38 sampled and screened in practice differ from their progenitors by only a small number of  
39 substitutions<sup>3</sup>, and optimization therefore proceeds as a “local walk” on a rugged fitness landscape<sup>3</sup>.  
40 Because protein function is shaped by epistasis and higher-order constraints, such local searches can  
41 become trapped on suboptimal peaks, leaving distant but potentially functional better-fitness regions  
42 of sequence space systematically underexplored<sup>3, 4</sup>. While deep mutational scanning and deep  
43 sequencing expanded access to large-scale sequence–function measurements<sup>5-7</sup>, they were also  
44 largely limited to local sequence space.

45

46 More recently, directed virtual evolution has emerged as a sequence-first alternative that learns  
47 surrogate fitness landscapes from sequence–function data and improves sequences by *in silico*  
48 search. Early work established probabilistic surrogate modeling, with Gaussian processes trained on  
49 measured activities to guide navigation of fitness landscapes.<sup>8, 9</sup> In parallel, structure-first pipelines  
50 such as AiCE integrate inverse-folding models with structural and evolutionary constraints to  
51 propose fold-compatible variants when reliable templates are available.<sup>10</sup> These approaches for  
52 directed virtual evolution can be grouped by how they obtain supervision and how far they can  
53 reliably search. One class relies on regression-style predictors trained on quantitative measurements  
54 (activity, fitness, binding, or other continuous phenotypes). These methods include deep supervised  
55 models or protein language models (PLM) with evolutionary context and active-learning pipelines  
56 for multi-round optimization such as ECNet<sup>11</sup> and EVOLVEpro<sup>12</sup>, active-learning evolution of  
57 artificial metalloenzymes by Vornholt and colleagues<sup>13</sup>, iterative deep-learning–guided directed  
58 evolution described by Li and colleagues<sup>14</sup>, and Active Learning-assisted Directed Evolution  
59 (ALDE) by Yang et al.<sup>15</sup> A second class focuses on improving label efficiency, exemplified by Low-  
60 N protein engineering, which trains data-efficient predictors from small labeled sets and then screens  
61 large virtual libraries.<sup>16</sup> A third class formalizes “design–test–learn” iteration and can be coupled to  
62 automated platforms or biofoundries for higher-throughput cycles, exemplified by the STAR web  
63 server<sup>17</sup> and biofoundry-integrated PLM workflows for automated protein evolution.<sup>18</sup> Despite  
64 substantial gains in these systems, the learned surrogates continue to be most reliable near the  
65 starting scaffold. That is, the search remains implemented as local exploration (for example, small-  
66 step mutation moves, Bayesian optimization, or iterative screening) rather than sampling remote,  
67 low-identity functional sequences directly.

68

69 Another limitation of the above methods is their reliance on strong, quantitative supervision. Many  
70 successful workflows train regression-style surrogate landscapes on continuous activity  
71 measurements, kinetic readouts, or well-calibrated phenotypes, often requiring hundreds to  
72 thousands of assayed variants per round to achieve predictive accuracy that is sufficient to guide  
73 search.<sup>12-14, 16, 19</sup> When the available signal is weaker—binary functional labels or enrichment  
74 counts from pooled selections—performance can degrade because the training objective becomes  
75 less informative per variant and experimental noise from low counts and sampling variance becomes  
76 a dominant factor that must be modeled carefully.<sup>6, 7, 20</sup> In practice, this data requirement can be the  
77 primary bottleneck early in a campaign, when only a small number of positives exist and quantitative  
78 characterization is costly or not yet available.

79

80 Here we introduce SPIN-dvEvo (Sequence Prediction with Integrated Neural networks – directed

virtual Evolution), a directed virtual evolution framework that unifies discovery and multi-round refinement in a single, sequence-first, low-data workflow. In contrast to conventional generative models that necessitate vast functional datasets, SPIN-dvEvo maintains high precision in label-scarce regimes by harnessing the evolutionary priors embedded within ESM-2<sup>18</sup> and fine-tuning its trajectory through lightweight LoRA.<sup>21</sup> The resulting model was employed as a scorer for directed virtual evolution powered by a genetic algorithm. SPIN-dvEvo was applied to virtually evolve TadA adenosine deaminase activity and the intrinsically disordered antitoxin CcdA. In both systems, only sparse binary functional labels were used to train a LoRA-based activity scorer on a frozen ESM-2 encoder, and candidate sequences were then generated by iterative mutation–crossover search guided by the fixed scorer, with additional feedback round performed for TadA by updating the LoRA head with newly obtained experimental labels. Experimental results confirmed the ability of SPIN-dvEvo to quickly evolve from a local cluster of a few highly homologous sequences to remote functional clusters.

## Results

### Directed virtual evolution by SPIN-dvEvo

The SPIN-dvEvo framework consists of two tightly coupled components: (i) a LoRA-adapted ESM-2 scoring model that trained task-specific functional scores using a small set of positive and negative sequences, and (ii) a genetic algorithm (GA) that directs sequence sampling and virtual evolution under this learned landscape. Each run starts from an initial seed pool generated by applying 20% random substitutions to the starting sequences. Here, SPIN-dvEvo was fine-tuned using only qualitatively labeled sequences with binary activity labels (1 for active, 0 for inactive) (Fig. 1).

### Directed virtual evolution from the neighborhood of an enzyme: TadA

To evaluate the enzyme-evolution capability of SPIN-dvEvo, we selected the tRNA-specific adenosine deaminase TadA as our model enzyme. TadA, originally evolved to target tRNA, has been engineered into adenine base editors that catalyze A•T→G•C conversions in DNA<sup>22</sup>. This system utilizes an R67 DHFR-based codon reversion reporter to rapidly detect the intracellular DNA-editing activity of evolved TadA variants, as in prior studies<sup>23, 24</sup>. In this codon reversion assay, an active variant reverts a premature TAG stop codon to TGG in the reporter, enabling growth under trimethoprim (TMP) selection (Fig. 2A). We quantified intracellular DNA-editing activity as the mutation frequency  $f = N_1 / N_0$ —the number of TMP-resistant revertants ( $N_1$ ) divided by the total number of viable cells plated without TMP ( $N_0$ )—and converted it into  $\mu_{s.p.b.}$  (per base per generation; See Methods).

We compiled a compact set of 10 TadA sequences spanning the wild type from *E. coli* (UniProt ID P68398) (Supplementary Table S1) and previously engineered active variants from *E. coli* with 6–20 mutations, (>88.6% sequence identity) and labeled all these sequences as 1. That is, we started with a sequence cluster of close functional neighbors. An equal number of 10 hypothetical inactive sequences were obtained by performing random mutations at 20% of positions in these TadA sequences (See Methods).

123 We then employed SPIN-dvEvo to produce (evolved virtually) 1,000 sequences by starting from the  
124 inactive sequences pool (20% random mutations). We confirmed that such virtual evolution started  
125 from a tightly clustered sequence region (in red) and quickly expands to other regions according to  
126 the t-SNE projection of ESM-2 sequence embeddings (**Fig 2B**).  
127

128 To examine whether the TadA function was preserved during the virtual evolution, we obtained  
129 sequence logos from 1000 natural TadA homologs compiled as in Ref<sup>25</sup> with a median sequence  
130 identity of 34.1% and compared them to sequence logos from 1000 evolved sequences (median  
131 identity 55.8%) in **Fig 2C**. The sequence motifs found previously<sup>26</sup> in the TadA family such as HAE  
132 and PCXXC zinc-dependent deaminase motifs and structural-core signatures EVP and TLE were  
133 also conserved in the evolved sequences while allowing substantial variation elsewhere. Thus,  
134 essential sequence information preserved in the natural sequences evolved over billions of years  
135 was captured by SPIN-dvEvo in a short 12 minutes of computing time with AMD EPYC 9654/ RTX  
136 4090 (24 GB) starting from a local sequence cluster around *E. coli* TadA.  
137

138 As protein structures play an essential role in enzymatic functions, we predicted structures of these  
139 evolved sequences and compared them to the structure of wild-type TadA (PDB ID:2B3J). We  
140 employed PLM-based OmegaFold<sup>27</sup> to make predictions because it does not require homologous  
141 sequences for input, and therefore permits fast, large-scale calculations for all 1000 evolved  
142 sequences. We obtained the distribution of structural accuracy (measured by TM-score<sup>28</sup>, 1 for  
143 perfect match and 0 for no match) for predicted structures of those evolved SPIN-dvEvo sequences  
144 and compared it to two baseline models PLM-based sequence generators Pinal<sup>29, 30</sup> and structure-  
145 based protein-design method ProteinMPNN<sup>31</sup>. ProteinMPNN employed a native structure template;  
146 Pinal was prompted with a natural-language TadA functional description (adenosine  
147 deaminase/base-editor context; EC 3.5.4.33) together with the wild-type TadA sequence (**Methods**).  
148 The results show that most evolved sequences given by SPIN-dvEvo adopted near-native structures  
149 (TMscore ~0.8, 89.6% sequences with TM-score>0.5), and was only slightly worse than the  
150 structure-based method ProteinMPNN (TMscore ~0.95) (**Fig. 2D**). The baseline sequence-based  
151 method Pinal shows a bimodal TM-score distribution, with one major peak at low TM-scores (~0.2–  
152 0.3, 53.9% sequences with TM-score<0.5) and another in the near-native range (~0.8–0.9),  
153 indicating a mixture of largely off-fold sequences and a smaller subset that retains the TadA fold.  
154 An example of a predicted structure for a SPIN-dvEvo sequence is compared to the native structure  
155 in **Supplementary Fig. 1**, highlighting near-perfect match, particularly in the regions interacting  
156 with a DNA substrate and near catalytic core.  
157

158 We further selected 60 evolved sequences to validate their enzymatic functions experimentally with  
159 the R67 DHFR–based codon reversion assay (**Fig. 2A**). These 60 sequences were selected from the  
160 above 1000 evolved sequences according to the high structure-confidence scores (normalized  
161 pLDDT> 0.9 given by AlphaFold 3<sup>32</sup> with a single natural MSA to save computing time) and low  
162 sequence identity ( $\leq 0.5$ ) to the wild type (as shown in **Fig. 2E**). Functional validation identified 23  
163 active variants out of 60 tested (38.3% success rate). Activities spanned more than three orders of  
164 magnitude, with several variants matching or exceeding the reference activity of *E. coli* TadA (**Fig.**  
165 **2F, Supplementary Fig. 2 A, Table S3, Table S4**). More importantly, these individually validated  
166 functional sequences span 39–79% amino-acid identity to the *E. coli* TadA wild type, confirming

167 the ability of SPIN-dvEvo to find functional solutions by going significantly beyond the immediate  
168 neighborhood of the starting sequences within the identity neighborhood of  $\geq 88\%$  *E. coli* TadA (**Fig. 2E**).  
169

170 Given 60 newly experimentally tested sequences, we re-trained the LoRA model with the enlarged  
171 binary-labelled dataset and performed sequence evolutions again by GA. The newly 1000 evolved  
172 sequences (Round II) are now forming new sequence clusters (Fig. 2B). The TMscore distribution  
173 of predicted structures for the second-round sequences improves over that of the first round. All  
174 predicted structures (100%) are now with TMscore  $> 0.78$  and the highest peak located at TMscore  
175 of 0.88, compared to 0.80 in the first round (**Fig. 2D**). We tested 60 new variants chosen according  
176 to high AlphaFold 3's pLDDT and low sequence similarity. In this second round, 31 of 60 new  
177 variants were active. The higher success rate in Round II than in Round I (51% versus 38.3%)  
178 indicates that incorporating new experimental labels with definitive inactive sequences improved  
179 the classifier-guided evolution (**Supplementary Fig. 2B, Table S3, Table S5**). Moreover, the  
180 measured activity for the functional sequences in the second round shifted upward relative to the  
181 first-round actives by one order of magnitude (**Fig. 2F**). These validated evolved sequences in  
182 Round II are more divergent from wild type (29–54% identity, compared to 39–79% in the first  
183 round; **Fig. 2E**), confirming the formation of new functional clusters with improved activity (**Fig. 2B**).  
184 This is remarkable considering the fact that only binary labels were employed to train SPIN-  
185 dvEvo.  
186

187 A few selected variants are illustrated along with positive and negative controls by plating on TMP-  
188 selective medium (dvTadA-55 and dvTadA-56 from round 1; dvTadA-2-02 from round 2). These  
189 evolved sequences produced markedly more TMP-resistant colonies than the negative control of  
190 expressing only an Xten linker-T7RNAP cassette in place of TadA and thus lacking deaminase  
191 activity and were comparable to the positive control (*E. coli* TadA) (**Fig. 2G**), consistent with robust  
192 in vivo editing activity.  
193

194

## 195 **Directed virtual evolution of intrinsically-disordered binder: anti-toxin CcdA**

196

197 To test whether SPIN-dvEvo can generalize beyond enzymes with well-defined structures to  
198 intrinsically disordered binding proteins, we applied it to the CcdA–CcdB toxin–antitoxin system.  
199 In *E. coli*, the antitoxin CcdA is a 72-residue protein. Here we only engineered its C-terminal  
200 segment (CcdA<sup>36–72</sup>, 36 residues), which mediates binding to CcdB and thereby blocks CcdB  
201 binding to GyrA to neutralize toxicity<sup>33</sup>. This 36-residue C-terminal domain is intrinsically  
202 unstructured prior to binding to CcdB<sup>33, 34</sup>. We started from the canonical *E. coli* CcdA (P62552),  
203 retrieved CcdA family homologs from closely related *Enterobacteriales/ Gammaproteobacteria*,  
204 removed incomplete or atypical entries as well as those sequences at 100% sequence identity cutoff.  
205 This yielded 22 close homologs (**Supplementary Table S2**) at 55.2–97.2% sequence identity. A  
206 LoRA head on a frozen ESM-2 encoder was fine-tuned on this curated set and then coupled to the  
207 GA to generate candidate binders, without introducing any CcdB sequence or structural information  
208 during training or sampling. We chose this CcdA–CcdB system because bacterial growth is  
209 directly correlated to the ability of the CcdA evolved by SPIN-dvEvo to bind and neutralize CcdB,  
210 enabling straightforward functional selection (**Fig. 3A**).

211  
212 As in the TadA case, we evolved 1000 CcdA variants by SPIN-dvEvo. As shown in **Fig 3B**, these  
213 sequences moved far away from the original sequence cluster and formed multiple clusters  
214 according to the t-SNE projections of the base ESM-2 embeddings. When we generated the  
215 sequence-logo from SPIN-dvEvo sequences (with a median sequence identity of 50.2%), it has  
216 similar sequence motifs as those from 100 natural homologs collected by querying the canonical  
217 ‘Antitoxin CcdA’ and filtering to a non-redundant set with a median sequence identity of 38.7%  
218 from UniProtKB, suggesting that key binding determinants preserved such as W44, E54,<sup>35</sup> G63,  
219 S64, F65, D71 and W72<sup>36, 37</sup>(**Fig. 3C**, blue box) in natural CcdA homologs were captured during  
220 virtual evolution by SPIN-dvEvo, despite that it was started from a highly local seed set.  
221

222 To test those sequences experimentally, we synthesized a library of 3,041 evolved CcdA variants  
223 and evaluated them using a pooled bacterial growth selection, because the ability for the bacterium  
224 to grow is correlated to the ability of the evolved CcdA to neutralize CcdB by binding (**Fig. 3A**).  
225 That is, the fitness of activity of CcdA variants can be measured by counting the number of a specific  
226 variant pre- and post-selections from high-throughput sequencing<sup>38</sup> (**Fig. 3A**). We estimated  
227 enrichment and uncertainty with the DiMSum pipeline<sup>39,40</sup> with Poisson–Delta variance modeling  
228 and overdispersion correction. Among 3,041 synthesized CcdA variants, only 2,363 variants were  
229 found with >30 reads and a minimum frequency of  $10^{-6}$  in both the pre-selection and post-selection  
230 libraries from high-throughput-sequencing data. Further application of an FDR-controlled filter  
231 relative to internal stop-codon negative controls of  $q\_value < 10^{-3}$  yielded 155 statistically  
232 significant functional variants (a 6.6% hit rate). We further employed an effect-size threshold to  
233 define more robust positives as those variants with  $\log_2(\text{fitness}) > 3.0$ , resulting in 62 active CcdA  
234 variants (a 2.6% hit rate, **Fig. 3D**). These variants contain 26 with  $\log_2(\text{fitness}) > 5$  and some  
235 comparable to the fitness of *E. coli* CcdA ( $\log_2(\text{fitness}) = 8.5$ ).  
236

237 To validate the above high-throughput result, we selected four variants around the stringent  
238 threshold of 3.0 with  $\log_2(\text{fitness}) = 3.3, 3.3, 3.2$ , and 3.0, respectively, along with two positive  
239 controls *E. coli* CcdA and an evolved variant with  $\log_2(\text{fitness}) = 5.3$  for in vivo functional testing  
240 (**Supplementary Table S7**). As shown in **Fig. 3E** by serial 10-fold dilution spot assays, we  
241 confirmed that all variants with  $\log_2(\text{fitness}) \geq 3.0$  are functional and the variant 878 with a larger  
242 fitness value has stronger growth. In particular, the variant 1654 with  $\log_2(\text{fitness}) = 3.0$  showed  
243 weak growth only at the dilution factor of  $10^2$ . It is noted that sequences with  $\log_2(\text{fitness}) \geq 3.0$   
244 retained only ~60–70% sequence identity to the *E. coli* CcdA (**Supplementary Fig. 3**), indicating  
245 substantial novelty among functional hits, given that only 36 residues were targeted for virtual  
246 evolution.  
247

## 248 Discussion

249 SPIN-dvEvo directly addresses a practical gap in current directed virtual evolution: most existing  
250 methods either require substantial labelled datasets to optimize a single scaffold locally, or function  
251 as one-shot generators whose sequences are not coupled to an explicit score-and-search loop that  
252 can be iterated with newly acquired labels. In contrast, SPIN-dvEvo mimics natural evolution by

254 employing a LoRA adaptor on the top of a frozen ESM-2 encoder to learn functional restraints. We  
255 showed that the functional restraints learned from a few dozen positive, binary-labeled samples of  
256 a highly homologous sequence cluster are sufficient to drive virtual evolution from dysfunctional  
257 sequences to functionally active proteins that are substantially away from original positive  
258 sequences by using a genetic algorithm. Some of these sequences, despite low sequence identity,  
259 are experimentally validated for their functions on two illustrative cases: enzymatic activity (TadA  
260 adenosine deaminase) and toxin-binding intrinsically disordered protein CcdA.

261

262 For virtual evolution of TadA enzyme, no structural information of was used to train SPIN-dvEvo  
263 and to drive evolution. Yet most evolved TadA variants have TadA structural folds (**Fig 2D**,  
264 **Supplementary Fig. 1**) in the first round (89.7% of sequences with predicted structural  
265 accuracy  $>0.5$  in TMscore). A minor peak with TMscore  $<0.5$  in the first round was eliminated after  
266 including experimental results from 60 variants (still in binary coding). The improved structural  
267 similarity to the wild type highlights the importance of a larger and cleaner dataset because in the  
268 first round, negatives represented by 20% random mutations may not be negatives. Interestingly, the  
269 second-round success rate increased from 38% to 51% along with a one-order-of-magnitude  
270 improvement in enzymatic activity, indicating that adding new experimental labels can improve  
271 classifier-guided search even for enzymatic activity, despite lacking quantitative labels.

272

273 We have selected sequences with high confidence in predicted structures for experimental  
274 validations. The high (38% in Round I) but not yet  $>90\%$  success rate for TadA's virtual evolution  
275 illustrates that the structural fold alone is not sufficient as an indicator of enzymatic activity. This is  
276 because enzyme function not only requires highly precise active-site geometry and transition-state  
277 stabilization, but also depends on compatible conformational dynamics and kinetics that enable  
278 efficient substrate binding and product release on a productive timescale.<sup>41-43</sup> More studies are  
279 needed to search for a better activity indicator as well as improving scoring for virtual evolution of  
280 enzymes.

281

282 SPIN-dvEvo evolved functional TadA starting from a 20% randomly mutated (inactive) seed. We  
283 kept starting sequences close to the TadA family where the LoRA scorer remains informative. We  
284 also tried to start from fully random sequences and found that evolution from these sequences is not  
285 productive according to analysis of their predicted structures. This indicates that the sequence space  
286 is too large to be located by starting from purely random sequences within practical GA generations.  
287 Nevertheless, it can start from one neighborhood of an active sequence to locate other  
288 neighborhoods far away from the original sequence cluster as shown in **Fig. 2B** and **Fig 3B**.

289

290 However, the success rate of SPIN-dvEvo for a disordered protein CcdA is only 2.6%. This is much  
291 lower than virtual evolution of TadA enzyme. Designing an intrinsically disordered protein is a  
292 challenging task because activity is typically encoded in an ensemble of rapidly interconverting  
293 conformations and mediated by weak, context-dependent interactions, so improvements in fold  
294 stability or a single “best” structure provide little guidance. Recent progress has come from  
295 explicitly optimizing ensemble-level objectives, for example by using sequence-to-ensemble  
296 predictors for IDRs and by combining generative models with biophysical/simulation-based  
297 forward models to design sequences that realize targeted disordered-state properties, as well as from

298 diffusion-based binder design strategies that focus the objective on functional binding constraints  
299 rather than enforcing an ordered fold.<sup>44</sup> Here, we achieved a success (albeit low success rate) without  
300 relying on any information from binding partner CcdB or predicted complex structures.

301  
302 It is of interest to know how new functional clusters would have been evolved naturally if they were  
303 mixed with natural homologs when building phylogenetic trees(see SI). As shown in **Fig. 4A** and  
304 **Fig. 4B**, both virtually evolved TadA and CcdA are forming several phylogenetically distinct  
305 clusters but do share common ancestors with naturally occurring sisters at different time points. For  
306 TadA, this split corresponds to an evolutionary timescale on the order of ~0.2–1.2 Ga, based on  
307 TimeTree-derived lineage-age estimates for these taxa<sup>45-47</sup>. Similarly, the estimates for the virtually  
308 evolved CcdA clade dating to approximately 2.508 Ga as diverging from a Gammaproteobacteria-  
309 associated branc. By comparison, these virtual evolutions took only 713 seconds for TadA and 761  
310 seconds for CcdA by SPIN-dvEvo on a workstation equipped with an AMD EPYC 9654 (96-core,  
311 2.4 GHz) CPU and an NVIDIA RTX 4090 GPU (24 GB).

312  
313 SPIN-dvEvo was purposefully trained on binary-labeled sequences (1 for functional and 0 for  
314 nonfunctional). This is because most proteins with known functions do not have a quantitative  
315 functional label. One immediate improvement for SPIN-dvEvo is to employ a regression head,  
316 rather than a classification head, when quantitative functional data such as a fitness score, binding  
317 affinity, or enzymatic activity is available for a small dataset. A regression head would contain a  
318 more accurate evolution direction than a classification head. This is a subject of an ongoing study.

319  
320 One limitation of SPIN-dvEvo is its reliance on the ESM-2 650M. While ESM-2 is one of the best  
321 protein language models available, we did not have the resource to test other language models or  
322 utilization of multiple language models that could be potentially more beneficial than ESM-2 in  
323 directed virtual evolution. Moreover ESM-2 may be inherently biased toward some protein  
324 sequences with large family of homologous sequences as it was indiscriminately trained on all  
325 protein sequences.<sup>48, 49</sup> Further studies in this area are needed.

326  
327 Moreover, current implementation of SPIN-dvEvo is optimized for a single functional objective. A  
328 multi-objective model, where functional objectives are optimized alongside other property  
329 objectives such as stability, pH tolerance, and thermostability, can be easily implemented. This  
330 research is also currently ongoing.

331

## 332 **Methods**

### 333 **Data Collection and Curation**

334 For TadA, we compiled 10 functional sequences from previously engineered DNA-editing TadA  
335 variants<sup>22</sup> (listed in **Supplementary Table S1**). For CcdA, we constructed the 22-sequence set by  
336 sequence-identity clustering of UniProtKB CcdA homologs. Starting from the canonical *E. coli*  
337 CcdA (P62552; 36 aa) as the query, we retrieved annotated CcdA family homologs from closely  
338 related *Enterobacteriales/Gammaproteobacteria*. We then removed incomplete/aberrant entries (e.g.,  
339 truncated sequences or atypical lengths) and identical sequences (100% sequence identity). This

340 yielded a deduplicated set by keeping only unique amino-acid sequences, yielding 22 non-redundant  
341 homologs (accessions in **Supplementary Table S2**). To balance classes during few-shot training,  
342 we generated synthetic decoys by randomly mutating 20% of residues in each positive sequence.  
343 All positive sequences were labeled as 1 (functional), and all negative sequences—whether  
344 randomly generated or literature-confirmed—were labeled as 0 (non-functional).

345

### 346 **LoRA-Based Model Adaptation**

347 We adapted ESM-2 (650M parameters) to each task using low-rank adapters (LoRA) while keeping  
348 all base model weights frozen. This model size offered a practical trade-off between representation  
349 quality and computational cost, allowing training on a single 24–40 GB GPU.

350

351 LoRA modules were inserted into the self-attention Q/K/V projection layers of every transformer  
352 block. For each pretrained projection  $W \in \mathbb{R}^{d \times d}$ , LoRA adds a trainable low-rank update  $\Delta W =$   
353  $s AB$  with rank  $r$  and scaling  $s = \alpha/r$ :

$$355 \quad \tilde{W} = W + s AB, A \in \mathbb{R}^{d \times r}, B \in \mathbb{R}^{r \times d}, s = \alpha/r.$$

354

355 We employed  $(r, \alpha) = (16, 16)$ . This setting adds 4,055,040 **LoRA** trainable parameters  
356 (excluding the final linear head), corresponding to ~0.62% of the ~650M-parameter ESM-2 base  
357 model, and was used throughout this work.

358

### 359 **Classification head (binary activity)**

360 For binary activity prediction  $y_i \in \{0, 1\}$ , the frozen ESM-2 produces a sequence representation  
361  $h \in \mathbb{R}^d$  (pooled from token embeddings), which is mapped to a scalar logit

$$362 \quad z = u^T h + b, \text{score} = f(x) = \sigma(z) \in [0, 1]$$

363

364 The classifier was trained with binary cross-entropy:

$$365 \quad \mathcal{L}_{\text{BCE}} = -\frac{1}{N} \sum_{i=1}^N [y_i \log p_i + (1 - y_i) \log (1 - p_i)].$$

366

367 Only the LoRA parameters ( $A, B$ ) and the classification head parameters ( $u, b$ ) were updated  
368 during training; all ESM-2 weights remained frozen,

369

370 Sequences were truncated to 1,000 amino acids and fine-tuned for 5 epochs using AdamW (learning  
371 rate  $5 \times 10^{-4}$ , weight decay  $10^{-3}$ ) with a cosine schedule and gradient clipping ( $\|\nabla\|_{\max} = 0.5$ ).  
372 LoRA adapters targeted the attention Q/K/V projections (rank  $r = 16$ ,  $\alpha = 16$ , dropout 0.2; base  
373 model frozen) with batch size 4.

374

### 375 **Genetic Algorithm Sampling**

376 We performed an iterative mutation–crossover search guided by a fixed LoRA activity scorer.  
377 Diversity arose implicitly from uniform parent sampling and stochastic point mutations, and exact  
378 duplicate children were removed during population construction. In each generation, parent  
379 sequences were sampled uniformly from the current mating pool and recombined to produce a child.

380

381 Each sequence was scored by the LoRA-adapted ESM-2 classifier, with the positive-class  
382 probability computed from the logits as

$$383 \quad p_{\text{act}}(x) = \frac{\exp(z_1)}{\exp(z_0) + \exp(z_1)}.$$

384 **Initialization.**

385 The initial population consisted of  $N$  sequences (equal to the size of the seed pool), generated by  
386 applying 20% random substitutions to a set of positive sequences (natural homologs or previously  
387 engineered variants).

388

389 **Embedding & activity model.**

390 Each sequence was scored by a LoRA-tuned binary activity classifier on a frozen ESM-2 (650M),  
391 returning  $p_{\text{act}}(x)$ . (Sequence embeddings  $\phi(x)$  were computed when needed for  
392 visualization/analysis, by mean-pooling the last hidden state over non-special tokens followed by  
393 L2 normalization.)

394

395 **Variation & constraints.**

396 Children were generated using a one-point crossover plus point-mutation operator  
397 (mutate\_crossover). One parent was first chosen as the base; a crossover point  $c \in [1, \min(|p_1|, |p_2|) - 1]$  was sampled, and the suffix was swapped with the other parent, yielding a recombinant  
398 whose length follows the suffix donor. After crossover, each position was independently mutated  
399 with probability 0.02 by substituting a uniformly sampled amino acid from the 20 standard residues.  
400 Candidate sequences were filtered with NCBI segmasker<sup>50</sup> to reject sequences containing low-  
401 complexity segments longer than 5 residues.

402

403 **Selection & replacement.**

404 For each parent sequence  $x$  with score  $p_{\text{act}}(x)$ , a child  $x'$  was proposed and evaluated to obtain  
405  $p_{\text{act}}(x')$ . The acceptance ratio was computed as

$$406 \quad r = \frac{p_{\text{act}}(x')}{p_{\text{act}}(x)}.$$

407

408 The child was accepted if  $r \geq 1$ ; otherwise, it was accepted with probability  $0.125 \times r$ . After  
409 iterating this accept/reject update across the population, sequences were ranked by score (by  $p_{\text{act}}$  in  
410 probability-only mode) and the top 25% sequences (ranked by score) were retained as the mating  
411 pool for the next generation. Unless stated otherwise, virtual evolutions were conducted for a pre-  
412 specified number of generations (default is 100) and the per-generation mean score was logged.

413

414 **Parallel runs.** Each run outputs  $N$  evolved sequences (set by the seed pool size). Larger libraries  
415 were obtained by launching multiple independent runs in parallel with different random seeds and  
416 by aggregating the resulting sequences.

417

418 **Sequence sampling of baseline models: ProteinMPNN and Pinal**

419 **ProteinMPNN**

420 A structure-templated baseline library was generated using ProteinMPNN in fixed-backbone design  
421 mode with the experimental TadA reference structure as the input template (PDB: **2B3J**, Chain A).

423 The structure file was preprocessed to retain only the designed protein chain (non-protein atoms  
424 were removed) and was provided to ProteinMPNN to compute per-position amino-acid distributions  
425 conditioned on the backbone coordinates. 1,000 sequences were then sampled stochastically from  
426 the model using temperature-controlled decoding (temperature = 0.1) with otherwise default  
427 ProteinMPNN settings. Sampled sequences were post-processed to remove exact duplicates and  
428 were written to FASTA for downstream structure prediction and evaluation.

429

### 430 **Prompt for Final Sequence Generation**

431 **TadA Prompt:** TadA (tRNA adenosine deaminase) is an enzyme that catalyzes the deamination of  
432 adenosine to inosine at the wobble position (A34) of tRNA molecules, thereby expanding codon  
433 recognition during translation, adenosine<sub>34</sub> in tRNA + H<sub>2</sub>O + H<sup>+</sup> = inosine<sub>34</sub> in tRNA + NH<sup>+</sup>.  
434 EC:3.5.4.33. Through the introduction of two key mutations, A106V and D108N, the substrate  
435 specificity of *E.coli* TadA has been reprogrammed, enabling the enzyme to catalyze adenosine and  
436 cytosine deamination directly on DNA substrates. These engineered TadA variants are incorporated  
437 into adenine base editors (ABEs), facilitating the precise conversion of A•T base pairs to G•C in  
438 DNA without introducing double-strand breaks. This strategy offers an efficient and high-fidelity  
439 tool for genome editing, particularly for the correction of disease-associated point mutations.

440

441 **CcdA Prompt:** CcdA is a bacterial antitoxin protein that functions as part of the CcdA–CcdB type  
442 II toxin-antitoxin system encoded by the F plasmid in *\*Escherichia coli\**. The CcdA protein  
443 comprises 72 amino acids and adopts a two-domain structure: an N-terminal dimerization and DNA-  
444 binding domain, followed by a C-terminal domain that binds to the CcdB toxin. In the absence of  
445 CcdB, the C-terminal domain of CcdA is intrinsically disordered. Upon binding to CcdB, CcdA  
446 undergoes a conformational change, forming a stable CcdA–CcdB complex that neutralizes the  
447 toxicity of CcdB. This complex also acts as a transcriptional repressor of the ccd operon by binding  
448 to the operator region. The CcdA–CcdB interaction is dynamic, with varying stoichiometries leading  
449 to different complex formations, including (CcdA)2–(CcdB)2 and (CcdA)2–(CcdB)4 complexes.  
450 The balance between CcdA and CcdB concentrations regulates the stability of the complex and the  
451 repression of the operon. CcdA is subject to degradation by the Lon protease, which modulates the  
452 levels of the antitoxin and, consequently, the activity of the toxin.",  
453

### 454 **Structure prediction for SPIN-dvEvo sequences**

455 SPIN-dvEvo sequences were evaluated by two complementary structure-prediction pipelines with  
456 distinct roles. For high-throughput, distribution-level benchmarking across large libraries, we used  
457 the MSA-free, PLM-based OmegaFold (v2.3.2)<sup>27</sup> to predict structures for all sequences, and  
458 quantified global fold similarity to experimental references using TM-align (TM-score). For TadA,  
459 PDB 2B3J (tRNA adenosine deaminase from *Staphylococcus aureus* in complex with RNA) was  
460 used as the reference structure, because it provides a substrate-bound, catalytically relevant  
461 conformation for a consistent TM-score fold-similarity benchmark; in contrast, the available *E. coli*  
462 TadA structure PDB 1Z3A is apo and does not capture the RNA-engaged state<sup>51</sup>. TM-scores reported  
463 in the main text refer to alignments between the native structure (PDB 2B3J) and OmegaFold-  
464 predicted structures for SPIN-dvEvo-evolved variants.

465

466 Separately, we used AlphaFold3 (AF3) to obtain model confidence estimates for experimental  
467 prioritization. To reduce the computational time for MSA retrieval, sequences were clustered at 80%  
468 pairwise identity; a representative sequence per cluster was used to query the AF3 MSA database,  
469 and the resulting MSAs were reused for all members of that cluster during the batch inference. For  
470 TadA, per-chain pLDDT was used as the confidence metric.

471

## 472 **TadA experimental methods**

### 473 **Reagents and Strains**

474 All PCR reactions for cloning restriction sites and generating recombineering targeting cassettes  
475 were performed using 2 × Phanta UniFi Master Mix DNA Polymerase (Vazyme, Nanjing, China,  
476 P516-02). Colony PCR reactions for subsequent sequencing were conducted using Premix Taq™  
477 DNA Polymerase (Takara, Dalian, China, R901A). Homologous recombination was performed  
478 using the CloneExpress II One Step Cloning Kit (Vazyme, C112-02). All primers were synthesized  
479 by GENEWIZ (Suzhou, China). Gene sequences for R67, which confers resistance to trimethoprim  
480 (TMP), and engineered TadA variants were synthesized by GENERAL BIOL (Anhui, China).  
481 Antibiotics, including ampicillin sodium (Sangon Biotech, Shanghai, China, A100339-0025) and  
482 chloramphenicol, along with L-arabinose, were obtained from commercial sources. Chemically  
483 competent *E. coli* DH5 $\alpha$  cells were purchased from AlpalifeBio (Beijing, China), and chemically  
484 competent *E. coli* DH10B cells were obtained from Biomed (Beijing, China).

485

### 486 **Plasmid construction**

487 Engineered TadA variants used in this study are detailed in **Tables S3**. Expression plasmids for these  
488 variants and T7 RNA polymerase (T7RNAP) were constructed using the pMuta088 vector backbone.  
489 This backbone, derived from pDae079, carries the tandem PmCDA1-T7 RNA polymerase and uracil  
490 glycosylase inhibitor (UGI).

491 For this study, expression plasmids for the engineered TadA variants were constructed by replacing  
492 the PmCDA1 gene in the pMuta088 scaffold with the specific TadA sequences via homologous  
493 recombination. A negative control plasmid (pT7RNAP- $\Delta$ TadA), expressing only an Xten-linker-  
494 T7RNAP cassette, was constructed using the same strategy.<sup>23</sup>

495

496 TadA editing activity was quantified by measuring the frequency of trimethoprim-resistant  
497 revertants following the general MutaT7/eMutaT7 workflow with minor modifications as detailed  
498 below.<sup>52</sup> To characterize the A•T-to-G•C editing activity of TadA variants via antibiotic resistance  
499 reversion, a reporter plasmid was developed. The *R67* gene, encoding dihydrofolate reductase  
500 (DHFR) which confers resistance to trimethoprim (TMP), was cloned into a low-copy-number  
501 plasmid (T7 promoter + terminators reporter plasmid). This was achieved by replacing the existing  
502 *neoR/ kanR* gene (from Tn5) in a precursor plasmid via homologous recombination. In the final  
503 reporter construct (pReporter-R67), expression of the *R67* gene is driven by a T7 promoter and  
504 transcription is terminated by a tandem array of ten T7 terminators. Subsequently, site-directed  
505 mutagenesis was employed to convert the tryptophan codon (TGG) at position 23 into a premature  
506 stop codon (TAG), resulting in the final reporter construct pReporter-R67<sup>W23\*</sup>. In this system, TadA-  
507 mediated adenine deamination reverts the stop codon to wild-type, thereby restoring functional R67  
508 expression and conferring TMP resistance.

509

510 **Evaluation of TadA Variant Activity in *E. coli***

511 To quantitatively characterize intracellular DNA-editing activity, the mutation (editing) frequency  
512 was defined as the ratio of the total TMP-resistant revertants to the total viable cell population.

513

514 To perform this assay, chemically competent *E. coli* DH10B cells were co-transformed with two  
515 plasmids: (1) The reporter plasmid (AmpR) pReporter-R67<sup>W23\*</sup>; (2) a chloramphenicol-resistant  
516 (CmR) expression plasmid (pDae079 derivative) encoding either pT7RNAP-ΔTadA (negative  
517 control), wild-type TadA (positive control), or an engineered TadA variant.

518

519 Transformants were selected on LB agar plates containing 100 µg/mL ampicillin and 25 µg/mL  
520 chloramphenicol, followed by incubation at 37°C for 12–16 hours. Individual colonies were then  
521 inoculated directly into 10 mL of LB broth supplemented with 100 µg/mL ampicillin, 25 µg/mL  
522 chloramphenicol, and 0.2% (w/v) L-arabinose, followed by overnight incubation (16 h) at 37°C with  
523 shaking at 220 rpm to initiate TadA expression and mutation accumulation.

524

525 On the following day, the overnight cultures were diluted 1:100 into fresh LB medium containing  
526 the same concentrations of ampicillin, chloramphenicol, and L-arabinose. To promote the fixation  
527 of mutations during active growth, these cultures were incubated for 4 hours at 37°C with shaking  
528 at 220 rpm.

529

530 **Editing activity Assay**

531 At the endpoint, cultures were serially diluted (10-fold). To determine the total viable cell population  
532 ( $N_0$ ), 10 µL aliquots of each serial dilution were spotted onto a single non-selective LB agar plate  
533 (containing 100 µg/mL ampicillin and 25 µg/mL chloramphenicol). To enumerate the TMP-resistant  
534 population ( $N_1$ ), 300 µL aliquots of undiluted culture were spread onto three selective LB agar plates  
535 containing 20 µg/mL TMP (supplemented with the same antibiotics). Plating for  $N_1$  was performed  
536 in triplicate. Colony counts were extrapolated to the full 10 mL culture volume to derive the total  
537 viable cells ( $N_0$ , scaled from the 10 µL spot and dilution factors) and total TMP-resistant revertants  
538 ( $N_1$ , scaled from the 300 µL spread). The frequency  $f$  was calculated as the ratio  $N_1 / N_0$ .

539

540 **Mutation-rate calculation.**

541 For cross-study comparison to prior eMutat7 reports, endpoint TMP-reversion frequencies were  
542 converted to per-base, per-generation mutation rates using the Luria–Delbrück rare-mutation  
543 approximation, where the expected mutant frequency satisfies  $E[f] \approx \mu \ln (R_{\text{eff}})$ . Although  
544 induction was maintained for 16 h, the calculation was normalized to the effective population  
545 expansion of the final outgrowth step, as mutation fixation is replication-dependent. This single 4 h  
546 propagation propagation round used a 1:100 reinoculation followed by regrowth to saturation,  
547 corresponding to  $\sim 6.6$  generations ( $G$ ). Assuming binary fission ( $R_{\text{eff}} = 2^G$ ),  $\ln (R_{\text{eff}}) =$   
548  $G \ln 2 \approx 4.57$ . Because TMP-resistance restoration of the R67 reporter requires a single-base  
549 reversion, the effective target size was set to  $S = 1$  and rates were reported as site-specific values  
550 (not normalized by the 192-bp reporter length):

551 
$$\mu_{s.p.b.} = \frac{f}{G \ln 2} \approx \frac{f}{4.57} \text{ (per base per generation)}$$

552

553 **Verification of R67 Gene Reversion**

554 To confirm that TMP resistance resulted from the targeted A•T-to-G•C edit in the *R67* gene, colony  
555 PCR was performed. For a representative subset of TadA variants tested, five independent TMP-  
556 resistant colonies were randomly picked from the selective agar plates for each selected variant. The  
557 *R67* gene locus was PCR-amplified from these colonies. The resulting amplicons were purified and  
558 subjected to Sanger sequencing (GENEWIZ, Suzhou, China). The obtained sequences were aligned  
559 with the reference *R67*<sup>W23\*</sup> sequence and the wild-type *R67* gene sequence to identify the specific  
560 A-to-G reversion at codon 23 and any other potential off-target mutations within the amplified  
561 region.

562

563 **CcdA library generation, selection, and validation**

564 **The Plasmids Construction**

565 The pUC57-Kan-ccdB plasmid was constructed to co-express the CcdA<sup>36-72</sup> domain and ccdB in  
566 *E. coli*. In this generation, the forward strand carries the J23119 promoter–driven CcdA<sup>36-72</sup> cassette,  
567 and the reverse strand carries the AmpR promoter–driven ccdB gene. A 21-bp spacer was inserted  
568 between the two stop codons to facilitate PCR amplification. Both ccdA<sup>36-72</sup> and ccdB were codon-  
569 optimized for *E. coli*, synthesized by General Biosystems, and subcloned into pUC57-Kan using  
570 PciI and NdeI restriction sites. For construction of the ccdA mutant library, we generated pUC57-  
571 Kan-2BspQI-ccdB by inserting two BspQI sites using primers BspQI-FP and BspQI-RP  
572 (**Supplementary Table S4**); this cloning step was performed in DB3.1 competent cells, which are  
573 resistant to ccdB toxicity. All plasmids were verified by Sanger sequencing, and complete vector  
574 and primer sequences are provided in **Supplementary Table S4**.

575

576 **Library Construction, Selection and High-Throughput Sequencing**

577 The SPIN-dvEvo-evolved ccdA<sup>36-72</sup> variants, codon-optimized for *E. coli*, were synthesized as an  
578 oligo pool containing the BspQI site by GenScript (China). The oligo pool was first amplified using  
579 PrimerSTAR HS DNA polymerase (Takara) and subsequently digested with BspQI. The digested  
580 fragments were then ligated into the BspQI-linearized pUC57-Kan-2BspQI-ccdB vector using T4  
581 DNA ligase (Takara). Finally, the ligation products were purified and eluted in nuclease-free water,  
582 ready for electroporation.

583

584 The ligation products were electroporated into electrocompetent DB3.1 cells using a Bio-Rad  
585 Micropulser according to the manufacturer's protocol. Transformants were recovered in 10 mL of  
586 LB medium at 37°C for 1 hour. To estimate the library size, a portion of the culture was serially  
587 diluted, plated on LB agar containing kanamycin, and incubated for colony counting. Meanwhile,  
588 kanamycin was added to the main culture to a final concentration of 50 µg/mL, followed by  
589 incubation at 37°C for 10 hours. Subsequently, 100 µL of this culture was inoculated into 10 mL of  
590 fresh LB medium for amplification and subsequent plasmid extraction. The remainder of the  
591 overnight culture was harvested, resuspended in LB medium with 15% glycerol, and stored at -80°C.  
592 The initial, unselected ccdA library consisted of plasmids extracted from the CcdB-resistant DB3.1  
593 strain. To perform functional selection, this library was electroporated into the CcdB-sensitive DH5 $\alpha$   
594 strain. Plasmids successfully recovered from DH5 $\alpha$  transformants then represented the selected  
595 ccdA library. The CcdA<sup>36-72</sup> gene was PCR-amplified from both libraries using INDEX-containing

596 primers. The amplicons were gel-purified and sequenced by Salus Pro platform (ShenZhen Salus  
597 Biomed Ltd)..

598

### 599 **In vivo functional analysis of the SPIN-dvEvo-evolved CcdA variants**

600 Selected CcdA variants (see **Supplementary Table S7**), encompassing a range of fitness scores,  
601 were cloned into a pUC57-Kan-ccdA/B expression vector. All gene sequences were synthesized and  
602 subsequently confirmed by DNA sequencing (General Biol). To evaluate *in vivo* function, 80 ng of  
603 each plasmid construct was transformed into the ccdB-sensitive *Escherichia coli* strain DH5 $\alpha$ .  
604 Transformants were selected on LB agar plates supplemented with kanamycin. A ten-fold serial  
605 dilution series of each transformation was plated to enable quantitative assessment. After incubation  
606 (37 °C, 20 h), colony-forming units (CFUs) were counted at matched dilution factors and reported  
607 as relative survival/growth under co-expression of ccdB, where functional CcdA variants rescue  
608 colony formation (**Supplementary Fig. 6**).

609

### 610 **Sequencing data processing**

611 Raw reads were demultiplexed, adapter-trimmed, and quality-filtered. Reads were assigned to  
612 SPIN-dvEvo-evolved variants by matching the variable region to the SPIN-dvEvo-evolved  
613 dictionary (allowing  $\leq 1$  mismatch to tolerate sequencing error; ambiguous matches were discarded).  
614 For each variant  $i$  counts  $c_i^{\text{pre}}$  and  $c_i^{\text{post}}$  were tabulated. Samples with  $<10^6$  total mapped reads  
615 were excluded. Unless noted, a small pseudocount ( $\alpha=0.5$ ) was used only for descriptive  
616 normalization of very low counts; final fitness estimates and uncertainty were obtained from  
617 DiMSum.<sup>39</sup>

618

### 619 **Fitness estimation and statistical analysis**

620 After read mapping and quality filtering, 2,363 SPIN-dvEvo-evolved variants were retained for  
621 downstream analysis. For each variant  $s$ , we denote the pre-selection and post-selection read counts  
622 as  $c_{\text{pre}}(s)$  and  $c_{\text{post}}(s)$ , with total library depths

$$624 N_{\text{pre}} = \sum_s c_{\text{pre}}(s), N_{\text{post}} = \sum_s c_{\text{post}}(s).$$

623

625 Counts were library-size normalized, and per-variant enrichment was defined as

$$627 ES(s) = \frac{c_{\text{post}}(s)/N_{\text{post}}}{c_{\text{pre}}(s)/N_{\text{pre}}}.$$

626

628 Variant fitness was then defined as the  $\log_2$  enrichment without any wild-type normalization:

$$630 F(s) = \log_2 ES(s) = \log_2 \left( \frac{c_{\text{post}}(s)}{c_{\text{pre}}(s)} \right) - \log_2 \left( \frac{N_{\text{post}}}{N_{\text{pre}}} \right).$$

629

631 Fitness ( $\log_2$  enrichment) and associated uncertainty were estimated with DiMSum (Poisson–Delta  
632 model with overdispersion correction), consistent with the definition above.

633

634 To identify significantly enriched variants, we applied an FDR-controlled significance filter based  
635 on DiMSum-reported  $q$ -values:

$$636 q_{\text{value}} < 10^{-3},$$

637

638 For effect-size stratification, we labeled variants with  $\log_2$  enrichment  $F(s) > 3.0$  as functional and  
639 those with  $F(s) > 5.0$  as wild-type-like

## 640 **Code availability**

641 The SPIN-dvEvo source code and the LoRA model weights for TadA and CcdA will be soon publicly  
642 available

## 643 **Data availability**

644 All data generated or analyzed in this study are included in the main text and Supplementary  
645 Information. Input and output sequence files (including training seeds, natural homolog sets, and  
646 evolved sequence libraries), as well as analysis-ready intermediate results, are publicly available at  
647 <https://zhouyq-lab.szbl.ac.cn/download/>. Additional materials are available from the corresponding  
648 authors upon reasonable request.

## 649 **Author Contributions**

650 ZC collected data, built the models, and performed sequence-based computational evolution. JT, TZ,  
651 and QN designed experiments and performed experimental validations. XZ helped with  
652 computational design. JZ and YZ initiated and supervised the project. YZ provided the funding  
653 support. YZ and ZC drafted the initial manuscript. All authors contributed to subsequent manuscript  
654 revision and approved the final version.

## 655 **Acknowledgements**

656 We thank the support for the National Natural Science Foundation of China (Grant Nos. 92370202)  
657 and the National Key R&D Program of China (Grant No. 2021YFF1200400). We also acknowledge  
658 the High Performance Computing Cluster at Shenzhen Bay Laboratory (SZBL) and the high-  
659 performance computing resources of the Shenzhen Medical Academy of Research and Translation  
660 (SMART) for computational support. Figure 2A was created with BioRender.com.

## 661 **Conflict of Interest**

662 All authors declare no financial interest. Jian Zhan is the founder and CEO of Ribopeutic, and Yaoqi  
663 Zhou is the scientific founder of Ribopeutic.

## 664 **Reference**

665

- 666 1. Arnold, F.H. Directed Evolution: Bringing New Chemistry to Life. *Angew Chem Int Ed Engl.* **57**,  
667 4143-4148 (2018).
- 668 2. Bloom, J.D. & Arnold, F.H. In the light of directed evolution: Pathways of adaptive protein  
669 evolution. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 9995-10000 (2009).
- 670 3. Tracewell, C.A. & Arnold, F.H. Directed enzyme evolution: climbing fitness peaks one amino acid  
671 at a time. *Curr. Opin. Chem. Biol.* **13**, 3-9 (2009).
- 672 4. Romero, P.A. & Arnold, F.H. Exploring protein fitness landscapes by directed evolution. *Nat. Rev.  
673 Mol. Cell Biol.* **10**, 866-876 (2009).

674 5. Fowler, D.M. & Fields, S. Deep mutational scanning: a new style of protein science. *Nature Methods* **11**, 801-807 (2014).

675 6. Wrenbeck, E.E., Faber, M.S. & Whitehead, T.A. Deep sequencing methods for protein engineering and design. *Curr. Opin. Struct. Biol.* **45**, 36-44 (2017).

676 7. Wong, T.S., Roccatano, D., Zacharias, M. & Schwaneberg, U. A Statistical Analysis of Random Mutagenesis Methods Used for Directed Protein Evolution. *J. Mol. Biol.* **355**, 858-871 (2006).

677 8. Romero, P.A., Krause, A. & Arnold, F.H. Navigating the protein fitness landscape with Gaussian processes. *Proc Natl Acad Sci U S A* **110**, E193-201 (2013).

678 9. Bedbrook, C.N. et al. Machine learning-guided channelrhodopsin engineering enables minimally invasive optogenetics. *Nat. Methods* **16**, 1176-1184 (2019).

679 10. Fei, H. et al. Advancing protein evolution with inverse folding models integrating structural and evolutionary constraints. *Cell* **188**, 4674-4692.e4619 (2025).

680 11. Luo, Y. et al. ECNet is an evolutionary context-integrated deep learning framework for protein engineering. *Nat Commun* **12**, 5743 (2021).

681 12. Jiang, K. et al. Rapid in silico directed evolution by a protein language model with EVOLVEpro. *Science* **387**, eadr6006 (2025).

682 13. Vornholt, T. et al. Enhanced Sequence-Activity Mapping and Evolution of Artificial Metalloenzymes by Active Learning. *ACS Central Science* **10**, 1357-1370 (2024).

683 14. Li, X. et al. An iterative deep learning-guided algorithm for directed protein evolution. *iScience* **28**, 113324 (2025).

684 15. Yang, J. et al. Active learning-assisted directed evolution. *Nat Commun* **16**, 714 (2025).

685 16. Biswas, S., Khimulya, G., Alley, E.C., Esveld, K.M. & Church, G.M. Low-N protein engineering with data-efficient deep learning. *Nature Methods* **18**, 389-396 (2021).

686 17. Yang, L., Liang, X., Zhang, N. & Lu, L. STAR: A Web Server for Assisting Directed Protein Evolution with Machine Learning. *ACS Omega* **8**, 44751-44756 (2023).

687 18. Zhang, Q. et al. Integrating protein language models and automatic biofoundry for enhanced protein evolution. *Nat Commun* **16**, 1553 (2025).

688 19. Yang, J. et al. Active learning-assisted directed evolution. *Nat Commun* **16**, 714 (2025).

689 20. Rubin, A.F. et al. A statistical framework for analyzing deep mutational scanning data. *Genome Biol.* **18**, 150 (2017).

690 21. Hu, J.E. et al. LoRA: Low-Rank Adaptation of Large Language Models. *arxiv* **abs/2106.09685** (2021).

691 22. Gaudelli, N.M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* **551**, 464-471 (2017).

692 23. Seo, D., Koh, B., Eom, G.-e., Kim, H.W. & Kim, S. A dual gene-specific mutator system installs all transition mutations at similar frequencies in vivo. *Nucleic Acids Res.* **51**, e59-e59 (2023).

693 24. Moore, C.L., Papa, L.J., III & Shoulders, M.D. A Processive Protein Chimera Introduces Mutations across Defined DNA Regions In Vivo. *J. Am. Chem. Soc.* **140**, 11560-11564 (2018).

694 25. Zhang, S. et al. TadA orthologs enable both cytosine and adenine editing of base editors. *Nat Commun* **14**, 414 (2023).

695 26. Yokobori, S.-i., Kitamura, A., Grosjean, H. & Bessho, Y. Life without tRNAArg–adenosine deaminase TadA: evolutionary consequences of decoding the four CGN codons as arginine in Mycoplasmas and other Mollicutes. *Nucleic Acids Res.* **41**, 6531-6543 (2013).

696 27. Wu, R. et al. High-resolution de novo structure prediction from primary sequence. *bioRxiv*,

718 2022.07.21.500999 (2022).

719 28. Zhang, Y. & Skolnick, J. TM-align: a protein structure alignment algorithm based on the TM-  
720 score. *Nucleic Acids Res.* **33**, 2302-2309 (2005).

721 29. Dai, F. et al. Pinal: Toward *De Novo* Protein Design from Natural Language. *bioRxiv*,  
722 2024.2008.2001.606258 (2025).

723 30. Yuan, J.S.a.C.H.a.Y.Z.a.J.S.a.X.Z.a.F. SaProt: Protein Language Modeling with Structure-aware  
724 Vocabulary. *ICLR 2024* (2024).

725 31. Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN.  
726 *Science* **378**, 49-56 (2022).

727 32. Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3.  
728 *Nature* **630**, 493-500 (2024).

729 33. Aghera, N.K. et al. Mechanism of CcdA-Mediated Rejuvenation of DNA Gyrase. *Structure* **28**,  
730 562-572.e564 (2020).

731 34. De Jonge, N. et al. Rejuvenation of CcdB-Poisoned Gyrase by an Intrinsically Disordered Protein  
732 Domain. *Molecular Cell* **35**, 154-163 (2009).

733 35. Bajaj, P., Manjunath, K. & Varadarajan, R. Structural and functional determinants inferred from  
734 deep mutational scans. *Protein science : a publication of the Protein Society* **31**, e4357 (2022).

735 36. Chandra, S., Manjunath, K., Asok, A. & Varadarajan, R. Mutational scan inferred binding  
736 energetics and structure in intrinsically disordered protein CcdA. *Protein science : a publication of*  
737 *the Protein Society* **32**, e4580 (2023).

738 37. De Jonge, N. et al. Rejuvenation of CcdB-poisoned gyrase by an intrinsically disordered protein  
739 domain. *Mol. Cell* **35**, 154-163 (2009).

740 38. Chandra, S. et al. The High Mutational Sensitivity of ccdA Antitoxin Is Linked to Codon  
741 Optimality. *Mol. Biol. Evol.* **39** (2022).

742 39. Faure, A.J., Schmiedel, J.M., Baeza-Centurion, P. & Lehner, B. DiMSum: an error model and  
743 pipeline for analyzing deep mutational scanning data and diagnosing common experimental  
744 pathologies. *Genome Biol.* **21**, 207 (2020).

745 40. Faure, A.J. et al. Mapping the energetic and allosteric landscapes of protein binding domains.  
746 *Nature* **604**, 175-183 (2022).

747 41. Lienhard, G.E. Enzymatic catalysis and transition-state theory. *Science* **180**, 149-154 (1973).

748 42. Hanson, J.A. et al. Illuminating the mechanistic roles of enzyme conformational dynamics. *Proc*  
749 *Natl Acad Sci U S A* **104**, 18055-18060 (2007).

750 43. Acevedo, O. & Jorgensen, W.L. Advances in quantum and molecular mechanical (QM/MM)  
751 simulations for organic and enzymatic reactions. *Acc. Chem. Res.* **43**, 142-151 (2010).

752 44. Lotthammer, J.M., Ginell, G.M., Griffith, D., Emenecker, R.J. & Holehouse, A.S. Direct  
753 prediction of intrinsically disordered protein conformational properties from sequence. *Nature*  
754 *Methods* **21**, 465-476 (2024).

755 45. Kumar, S. et al. TimeTree 5: An Expanded Resource for Species Divergence Times. *Mol. Biol.*  
756 *Evol.* **39** (2022).

757 46. Feng, D.-F., Cho, G. & Doolittle, R.F. Determining divergence times with a protein clock: Update  
758 and reevaluation. *Proc Natl Acad Sci U S A* **94**, 13028-13033 (1997).

759 47. Konaté, M.M. et al. Molecular function limits divergent protein evolution on planetary timescales.  
760 *eLife* **8** (2019).

761 48. Ding, F. & Steinhardt, J. Protein language models are biased by unequal sequence sampling across

762 the tree of life. *ICLR 2024 Workshop on Generative and Experimental Perspectives for*  
763 *Biomolecular Design*, 2024.2003.2007.584001 (2024).

764 49. Notin, P. et al. in Proceedings of the 39th International Conference on Machine Learning,  
765 *Proceedings of Machine Learning Research* **162**. 16990--17017 (2022).


766 50. Madden T, C.C. BLAST+ features. *National Center for Biotechnology Information (US)* (2008).

767 51. Rallapalli, K.L., Ranzau, B.L., Ganapathy, K.R., Paesani, F. & Komor, A.C. Combined  
768 Theoretical, Bioinformatic, and Biochemical Analyses of RNA Editing by Adenine Base Editors.  
769 *The CRISPR journal* **5**, 294-310 (2022).

770 52. Park, H. & Kim, S. Gene-specific mutagenesis enables rapid continuous evolution of enzymes in  
771 vivo. *Nucleic acids research* **49**, e32 (2021).

772


773



774


775 **Figure 1. Schematic overview of the framework for directed virtual evolution: SPIN-dvEvo.** A  
776 LoRA-adapted ESM-2 model is fine-tuned utilizing only a few curated positive and randomly  
777 generated negative (binary) samples. The model is then integrated into a genetic algorithm as a  
778 scorer to iteratively evolve sequences toward desired functionality but away from the original  
779 sequence cluster.

780



782 **Figure 2. Validation of virtually evolved enzyme TadA from sequence motifs, predicted structures**  
783 **and experiments.** **(A)** Schematic of the experimental reporter system employed for quantifying A•T-  
784 to-G•C editing activity. TadA-mediated reversion of a premature TAG stop codon to a TGG codon  
785 in the *R67* gene confers resistance to trimethoprim (TMP), enabling selection of active variants. **(B)**  
786 Newly emerged clusters from directed virtual evolution by SPIN-dvEvo according to the t-SNE  
787 projections of the base ESM-2 embeddings of the 10 starting TadA sequences to 1000 evolved  
788 sequences in Round 1 and Round 2. **(C)** Similar conserved functional and structural core motifs  
789 between virtual evolved sequences and natural homologs (top). **(D)** The accuracy for the predicted  
790 structures (according to TMscore) for 1000 TadA variants generated by four models (sequence generators  
791 Pinal and structure-based designs ProteinMPNN) compared to those given by SPIN-dvEvo in two rounds.  
792 **(E)** Scatter plot of the predicted confidence score pLDDT versus sequence identity to the wild type  
793 (*E. coli* TadA) for 1000 evolved sequences by SPIN-dvEvo in Round 1 and Round 2. The 60  
794 experimentally tested sequences selected from Round 1 and the 60 from Round 2 are highlighted as  
795 filled points. **(F)** Boxplots comparing experimental activities of validated first- and second-round  
796 evolved TadA sequences, showing an upward-shifted distribution after including the first-round  
797 result in training. **(G)** Illustrative examples of the plates from the R67 DHFR-based *E. coli* reporter  
798 assay on TMP-selective medium. Shown are the negative control ( $\Delta$ TadA cells only expressing Xten  
799 linker-T7RNAP), a positive-control TadA variant (*E. coli* TadA), and cells expressing SPIN-dvEvo-  
800 evolved TadA variants dvTadA-55, dvTadA-56 and dvTadA-2-02.

801




802

803 **Figure 3. Experimental validation of evolved variant library of intrinsically disordered protein**  
 804 ***CcdA*.**

805 (A) Schematic diagram for high-throughput validation of evolved *CcdA* according to the ability of  
 806 a *CcdA* variant that can neutralize *CcdB* toxin in *E. coli* growth, measured by sequence counts pre  
 807 and post selections. (B) Emergence of new clusters in SPIN-dvEvo sequences evolved from the  
 808 starting 22 natural *CcdA* input sequences according to the t-SNE projections of the base ESM-2  
 809 embeddings. (C) Sequence motifs from SPIN-dvEvo sequences are highly similar to those obtained  
 810 from natural homologs according to key conserved residues highlighted in blue boxes. (D) The  
 811 distribution in number of variants as measured fitness scores (Log<sub>2</sub> fitness distributions normalized  
 812 by the library size). (E) Activity confirmation of selected variants according to their fitness. Serial  
 813 10-fold dilution spot assay showing *CcdA* WT from *E. coli* and five *CcdA* variants (1654 (Log<sub>2</sub>  
 814 fitness = 3.0), 924 (Log<sub>2</sub> fitness = 3.2), 903 (Log<sub>2</sub> fitness = 3.3), 854 (Log<sub>2</sub> fitness = 3.3), and 878  
 815 (Log<sub>2</sub> fitness = 5.3) along with the wild type (Log<sub>2</sub> fitness = 8.5)) for rescuing toxin *CcdB* at a  
 816 dilution factor of 10<sup>2</sup>–10<sup>4</sup>. Higher colony counts indicate stronger neutralization activity.

817



819 **Figure 4. Phylogenetic novelty of SPIN-dvEvo TadA and CcdA variants in joint natural-  
820 evolved trees.**

821 Maximum-likelihood phylogenies inferred from multiple sequence alignments containing natural  
822 homologs and experimentally validated SPIN-dvEvo evolved variants (sequences combined prior  
823 to alignment and tree building). Triangles denote nodes with bootstrap support in the 70–100  
824 range. **(A)** TadA: alignment includes 1000 natural TadA homologs and 54 dvTadA variants.  
825 Highlighted sectors mark major, evolve-enriched dvTadA branches separated from dominant  
826 natural clades, supporting phylogenetically distinct lineages beyond the initial natural  
827 neighborhood. **(B)** CcdA: alignment includes 100 natural CcdA homologs and 62 dvCcdA  
828 variants. Light-blue and red sectors highlight two major evolved dvCcdA branches, indicating  
829 phylogenetically distinct lineages relative to the bulk of natural homologs.

830  
831